Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Thx explains todays action. $JPEX someone running game today.
$JPEX LOL how this got stickied just silly. No evidence of P&D
Yes good call. Done!
Slackers at commission doing what they do best today it seems, NOTHING!!! Not 1 Opinion issued this week thus far. 4 Extensions though yesterday, whatever they are doing looks like they need more time to do it.
$DBMM SET US FREE....Issue the FD already.
I think that is good removes a step from Expert to Pink Markets in $DBMM's case. Could very well go Pink day after FD is issued.
All filings are UTD and Audited 10K's $DBMM is an SEC Filer.
Looking good so far steady. $JPEX
PEPSI in da house. $JPEX
Always good to see you on a mutual ticker.
GM $JPEX lets have a good day. Stock trading out of trips this week. Buying has been very encouraging last few sessions.
SEC loves to delay on their end. New Motto should be "Kicking Cans and Sitting on Hands"
He is right some do get extended and then they put a exact date as to when a FD will be issued.
You can find it on SEC website under litigations.
https://www.sec.gov/page/aljsectionlanding
Go to Enforcements and then Opinions.
For sure Trip plays always have that hanging over it, As far as what is coming just a feeling and when it drops it will create MOMO and let those who loaded up out with profit while those not willing to gamble on this "POS" will be left scratching their collective heads.
OTC is landmines at best. Learning how to navigate them and recognizing patterns is why 5% make money and the rest don't.
$GRSO GLTY and correct if you don't know how to play Stinky Pink Trips plays don't gamble on them.
$ICNM time running out on OTC turd stocks like this SEC crackdown coming. 60 day timeclock has started Sept 16/2020.
Must read.
https://www.sec.gov/news/press-release/2020-212
Must either get this cleaned up and sold.
Yesterday's front load always an indication of something coming.
$GRSO
What are you talking about this is not Grammar school this is about Law Precedence and misguided over zealous SEC Enforcement.
Plain and simple Samantha M. Williams, David S. Frye, and Stephan J. Schlegelmilch for the Division of Enforcement, Securities and Exchange Commission asked for too much and were not allowed to get what they asked for under the LAW related to the OIP.
Definitely outclassed and led down the garden path into the trap set by Maranda Fritz, of Thompson Hine LLP, for Digital Brand Media &
Marketing Group, Inc.
LOL Wrong!
So I see where you are getting lost here now. Before I didn't understand why you couldn't see what we see.
Seems you omitted the biggest piece of the decision. No one is contending that they were at one point delinquent on filings but where not delinquent when case was brought to Docket for AJL to hear case Nov, 12/19.
The Division cites American Steller Energy, Inc. (n/k/a Tara Gold Res. Corp.), Exchange
Act Release No. 64897, 2011 SEC LEXIS 2455 (July 18, 2011) (Tara Gold), to support its
argument that Digital Brand’s comprehensive filings do not shield it from revocation. However,
Digital Brand’s reporting is distinguishable from Tara Gold’s. Tara Gold had a nine-year period
of delinquencies, promised to make various overdue filings by dates that it did not meet, and
failed to include various material information in the filings it did make.
While revocation is not “necessary or appropriate for the protection of investors,” neither
is suspension. Digital Brand’s reporting is now current, but suspension would relieve it of the
requirement of filing periodic reports for the period of the suspension. Depriving investors of
current financial information would be an undesirable consequence of a suspension and, contrary
to the primary purpose of the reporting requirements of the Exchange Act, antithetical to “the
protection of investors.” Even so, Digital Brand should be aware that further violations of its
periodic reporting timeliness and completeness obligations may mark it as a recidivist and invite
further scrutiny from Commission staff.
In conclusion, the violations alleged in the OIP are proven, but no available sanction is
appropriate. Thus, this proceeding will be dismissed.
V. ORDER
IT IS ORDERED that this administrative proceeding IS DISMISSED.
Laboratory Testing of Brilacidin for COVID-19 in Combination with Remdesivir Reduces Viral Load by Nearly 100 Percent
Brilacidin and Remdesivir shown to act synergistically in vitro, increasing overall inhibition against the novel coronavirus to 99.85 percent in a human lung cell line
Data suggest that Brilacidin and Remdesivir, with different but complementary primary mechanisms of action, may be an especially potent combination in treating COVID-19
WAKEFIELD, Mass., Sept. 15, 2020 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, reports today receiving additional data from a U.S. Regional Biocontainment Laboratory (RBL) collected during ongoing in vitro testing supporting Brilacidin as a potential treatment for SARS-CoV-2, the novel coronavirus responsible for COVID-19.
In human lung epithelial cell line experiments performed at the RBL, Brilacidin in combination with Remdesivir, compared to Remdesivir-only treated conditions, showed a statistically significant and synergistic inhibition of SARS-CoV-2. Of particular note, overall viral load was reduced by 99.85 percent in one combination experiment, with remaining virus dropping to near undetectable levels.
Brilacidin appears to have primarily an extracellular mechanism of action, by disrupting viral integrity and blocking viral entry. In contrast, Remdesivir—currently authorized by the FDA for emergency use against COVID-19—has an intracellular mechanism of action, affecting viral replication post-infection. Exhibiting different but synergistic antiviral properties, these two drugs may be an especially potent drug combination in treating COVID-19.
“The Brilacidin and Remdesivir in vitro combination results are compelling,” commented Leo Ehrlich, Chief Executive Officer at Innovation Pharmaceuticals. “As we prepare to initiate our own clinical testing of Brilacidin for COVID-19 as a standalone therapy, given its consistent and robust antiviral activity, these latest test results indicate that combination trials with other drugs may be warranted. To that end, the company is pursuing grant opportunities with potential for larger, government-funded clinical trials. Such trials might include options for administration of Brilacidin in combination with Remdesivir, the world’s leading frontline COVID-19 treatment.”
Ehrlich continued: “It is exciting as we now rapidly transition from laboratory testing to the clinical testing of Brilacidin in hopes of treating COVID-19. Public reticence to use vaccines, alongside questions surrounding vaccine safety, efficacy, and timing of availability, further support the critical need for a promising drug like Brilacidin to emerge in the global fight against COVID-19.”
In other newly conducted lab testing at the RBL, Brilacidin was shown to inhibit SARS-CoV-2 in a human intestinal epithelial cell line and in primary fibroblast cells obtained from human donors. The Company has been informed by the RBL that it is nearing completion of its in vitro testing of Brilacidin against SARS-CoV-2 and will be submitting findings for peer-review publication. The publication will be solely focused on Brilacidin, with a pre-print made available.
Global COVID-19 Cases and Mortality
An online tool tracking COVID-19 cases and mortality, both in the U.S. and globally, can be found on the Company’s website (http://www.ipharminc.com), and at the following link: https://ipixcovid19tracker.com/
For researchers and institutions interested in collaborating on Brilacidin for COVID-19, please send inquiries to: covid19@ipharminc.com
Brilacidin and COVID-19
Brilacidin is one of the few drugs targeting COVID-19 that has been tested in human trials (a total of 8) for other clinical indications, providing an established safety and efficacy database on over 460 subjects, thereby potentially enabling it to rapidly help address the novel coronavirus crisis. Ongoing laboratory testing conducted at a U.S. Regional Biocontainment Laboratory (RBL), and at a Public Health Research Institute (PHRI), supports Brilacidin’s antiviral ability to safely inhibit SARS-CoV-2 in both human and animal cell lines. A molecular screening study of 11,552 compounds also supports Brilacidin as a promising novel coronavirus treatment. Additional pre-clinical and clinical data support Brilacidin’s potential to inhibit IL-6, IL-1ß, TNF-a and other pro-inflammatory cytokines and chemokines, which have been identified as central drivers in the worsening prognoses of hospitalized COVID-19 patients. Brilacidin’s robust antimicrobial properties might also help to fight secondary bacterial infections, which can co-present in up to 20 percent of COVID-19 patients. These data collectively support Brilacidin as a unique 3 in 1 combination—antiviral, immuno/anti-inflammatory, and antimicrobial—anti-COVID-19 therapeutic candidate.
Precisely as I have come to understand many people do not understand S/H's of record.
It is not you and me it is the Brokerages.
Commission can either uphold the Judges ID and issue a FD to that effect clearing the way for $DBMM to do a tier change to pink. Or they can consider the PFR from SEC Enforcement filled with new precedence being cited. Which was not there in their court case. "Moving the Goalposts" in a Hail Mary to get some sanctions placed on $DBMM which will no be revocation due to being Current with filings before the case hit the docket and sustained since then.
Their is no need to punish S/H's further by revoking the Share Classes on a Current operating entity with revenues.
Maybe a fine IDK. Previous experience in Sanctions says 50K Max but never been in something like this so anything I say is opinion.
No Red Tape on it IMO they are avoiding the obvious. They lost and it stings. They are issuing Opinions on cases sent to commission after the Judge ruled for $DBMM and SEC Enforcement sent in PFR.
This is the Commission failing to execute their duties in a timely manner probably because of repercussions it will have on cases going forward.
Commission needs to get off their collective overpaid fat asses and ACT!!!!
Uphold the Judges decision to Dismiss!
Probably the $DBMM ruling is going to set a new precedence that they are going to have to contend with for the long term. My guess is they are working on amendments to the laws governing OIP punishment's and the benchmarks needed to institute them in the future.
It isn't far fetched for that to happen since all they have done since SEC CorpFin signed off on Filings is try to move the goalpost and after DISMISSAL they tried to switch the damn field.
He is serious. So if you don't mind get on that ASAP. LOL
$DBMM have a good weekend.
$DBMM Not sure about 300M NSS or not. People are here and bought shares for the possibility of a payday pure and simple. Now it is their own money and for myself mine. I will speak for myself when I say that I am here for Initial Decision (Dismissed) being upheld via Final Decision.
We all know or at least should know that SEC Enforcements case is very weak not because OIP could not be proven but they couldn't prove their case with certainty in SEC Law and used a Multiple Precedent attack that was flawed (one named Tara Gold the most conspicuous).
Now they (SEC Enforcement) on Dec 3, 2019 filed a petition for review "PFR" where because their attempt to cut $DBMM down and get them revoked failed based on Flawed Precedence or plain incompetence or both.
PFR uses even more Precedents Impax Laboratories, China Biotics & Gateway Intl Holdings. Obviously just keep throwing shit on the wall to see what sticks. They will fail once commission gets around to $DBMM PFR.
So much energy trying to tear down a Grey Stock that folks are taking a flier on is not the best use of time. But to each his own.
For me I will continue to make money on the Live tickers while I wait for SEC Commission to get off their overpaid asses.
GLTA and Have a good weekend.
$DBMM SEC Commission a whopping 3 (No Brainer) Opinions this week. Way to not over exert yourselves you bunch of overpaid slackers.
Good stuff. Catalysts about to start dropping. Kind of glad they are not fluffing this lets me add.
$DKSC
Ask getting nibbled on everyday it seems. Gonna Need a Great White Feeding frenzy to have any effect on the Turd named $ICNM though!
Thought SEC was afraid of doing the work on more complicated matters. but then they file this today. Maybe they do have it within them to tackle $DBMM and issue FD.
https://www.sec.gov/litigation/opinions/2020/33-10834.pdf
Looks not that simple.
Takes some time for IHUB and OTCM to capture filings from Edgar. Sometimes a few hours.
Here it is.
https://www.sec.gov/Archives/edgar/data/0001075857/000149315220017280/form10-q.htm
SEC Commission day off probably no filing today. $DBMM waits for no one except the Dang SEC slackers.
$DBMM SEC Commission is doing the easy OIP's it seems maybe this is too much work for their overpaid asses.
Slackers and Gov't salaries!! Always looking for what is the easy way to fill the day.
Please read entire post before posting.
What do you expect them to say while SEC is still in process of getting a decision. They can't say anything!.
$DBMM
SEC Insiders buying today....We have a leak!!! Kidding of course people buying lotto tickets to the Chicken Dance $DBMM
$RBII putting up a fight with SEC.
I know where lots of the buys came from. People are loading Lotto here today. All good. Groups took notice but no one went massive. Just enough.
GM hope today is the day for FD. $DBMM
Nice dig so 4 today and 1 with our Mutual Lawyer. Getting there bit by bit.